Life Sciences

  • August 10, 2026

    Fed. Circ. Reverses PTAB On Prior Art Issue Over Dental IP

    The Federal Circuit on Monday reversed a Patent Trial and Appeal Board decision that invalidated a group of claims in a Dental Monitoring SAS dental imaging patent, finding that a previous provisional patent application was missing a written description and thus can't be used as prior art.

  • August 10, 2026

    Judge Blocks DOD Military Label For Chinese Biotech Co.

    A D.C. federal judge temporarily blocked the U.S. Department of Defense from enforcing a decision to designate WuXi AppTec Co. Ltd. as a Chinese military company, ruling the department's justifications appeared to lack a grounding in the evidence they cited.

  • August 10, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court last week tackled disputes involving merger settlements, contract claims, controlling stockholders, music rights, prejudgment interest, absentee voting and stockholder standing.

  • August 10, 2026

    Jazz Pharma Buying Actio In Up To $1.32B Epilepsy Push

    Dublin-based Jazz Pharmaceuticals PLC said Monday it will pay up to $1.32 billion for privately held Actio Biosciences, with Hogan Lovells Cadwalader advising Jazz and Cooley LLP guiding Actio. 

  • August 10, 2026

    EU Sets Antidumping Duties On Plastic Compound Imports

    A chemical compound used in plastic production has been found to have been sold at less than fair value in the European Union, and imports from South Korea and Mexico will face antidumping duties, the European Commission announced Monday.

  • August 07, 2026

    3rd Circ. Says Pharma Co. Suit Against Merck Belongs In India

    The Third Circuit has ruled that a dispute between Merck and a defunct Indian pharmaceutical company over a terminated relationship belongs in India.

  • August 07, 2026

    VA To Test Psilocybin For Veterans With Severe Depression

    Former military service members in five U.S. cities will have an opportunity to treat their depression with psilocybin through a clinical trial being run by the U.S. Department of Veterans Affairs, according to an agency announcement.

  • August 07, 2026

    Glenmark's $29.6M Generics Price-Fixing Deal Gets 1st OK

    A Connecticut federal court on Thursday gave a preliminary OK to a settlement between a coalition of 48 states and territories and drugmaker Glenmark Pharmaceuticals Ltd. that would pay out more than $29.6 million in restitution to eligible consumers and the coalition.

  • August 07, 2026

    J&J Fax Sent To Pharmacy An Unwanted Ad, 3rd Circ. Says

    In a precedential opinion Friday, the Third Circuit ruled a two-page fax Johnson & Johnson sent to a Florida pharmacy about its drug Xarelto was an unsolicited advertisement, reversing a lower court's finding and reviving a class claim filed by the pharmacy alleging the drugmaker violated the Telephone Consumer Protection Act.

  • August 07, 2026

    New Squires Order Institutes 4 Patent Reviews, Denies 6

    U.S. Patent and Trademark Office Director John Squires has instituted review of four patents and denied six other petitions in his latest round of decisions.

  • August 07, 2026

    KKR Buying Medicover's India Business In $1.4B Deal

    Global investment firm KKR has agreed to acquire Medicover Hospitals India, Swedish healthcare provider Medicover AB's Indian hospital operations business, in a transaction that values the platform at about €1.2 billion ($1.4 billion).

  • August 07, 2026

    Nat'l Science Org. To Review Judiciary's Nixed Climate Chapter

    The National Academy of Sciences will review the process used to develop a controversial chapter on climate science that has been removed from the federal judiciary's guide to scientific evidence, according to a Friday announcement.

  • August 07, 2026

    Eli Lilly Launches Attacks On Tirzepatide Generics

    Eli Lilly and Co. fired off a round of lawsuits in Delaware federal court seeking to block generic versions of its tirzepatide weight loss and diabetes medications, targeting Sandoz, MSN Laboratories and others.

  • August 07, 2026

    Cooley Leads 2 Biotech Firms Pricing IPOs Totaling $496M

    Two biotechnology firms began trading publicly Friday after raising a combined $496 million in their initial public offerings, with Cooley LLP advising both companies and Latham & Watkins LLP advising both underwriters.

  • August 07, 2026

    Taxation With Representation: Slaughter And May, Covington

    In this week's Taxation With Representation, U.K. real estate investment trust Segro's board agrees to a share offer from U.S. rival Prologis with a partial cash alternative, Curium acquires fellow radiopharmaceutical company Lantheus Holdings Inc., and investment firm KKR buys medical device company Integer Holdings Corp.

  • August 06, 2026

    Mead Preemption Bid Fails Before 1st Baby Formula MDL Trial

    An Illinois federal judge on Wednesday said Mead Johnson & Co. must face the first bellwether trial next week in multidistrict litigation over baby formula that allegedly was defective and harmed premature babies, rejecting the company's argument that the recent U.S. Supreme Court Monsanto decision blocks the plaintiff's claims.

  • August 06, 2026

    USPTO Leaders Reinstate Double Patenting Ax In Sanofi Case

    A panel including U.S. Patent and Trademark Office Director John Squires ruled Thursday that a Sanofi patent application must be rejected for double patenting, but questioned whether the rationale for the decision risks harming innovation and should be reconsidered by the Federal Circuit.

  • August 06, 2026

    Mark Zuckerberg's Foundation Can Arbitrate Gender Bias Suit

    A California federal judge on Thursday sent to arbitration claims that the foundation run by Meta CEO Mark Zuckerberg and his wife Priscilla Chan discriminated against women, saying the suit's sexual harassment claims weren't sufficiently severe or pervasive to invalidate the plaintiff's arbitration agreement.

  • August 06, 2026

    SEC Nets Win In Suit Over Ex-CEO's Alleged Revenue Scheme

    A Washington, D.C., federal judge on Thursday largely sided with the U.S. Securities and Exchange Commission in its civil enforcement case against the former CEO of RTI Surgical Holdings, finding he misled investors by failing to disclose that the surgical implant company regularly shipped orders early to artificially inflate its quarterly revenues.

  • August 06, 2026

    SpineFrontier CFO Sentenced To 4 Months In Kickback Case

    The former chief financial officer of spinal implant startup SpineFrontier was sentenced Thursday to four months in prison for his involvement in an alleged conspiracy to pay surgeons kickbacks disguised as consulting fees.

  • August 06, 2026

    GOP Sens. Vote To Hold Fauci In Contempt, AGs Open Probe

    A U.S. Senate committee voted along party lines Thursday to hold Dr. Anthony Fauci in contempt of Congress after he declined to answer questions about the government's handling of the pandemic, while the Florida, West Virginia and Louisiana attorneys general are investigating potential "self-dealing" by Fauci during the crisis.

  • August 06, 2026

    Judge Sets Feb. Trial In States' Generics Price-Fixing Suit

    A Connecticut federal judge has set a February trial date on claims from dozens of state attorneys general that generic-drug makers conspired to artificially inflate the prices of generic topical drugs.

  • August 06, 2026

    Goodwin, Covington Lead Braveheart Bio's $383M IPO

    Venture-backed biotechnology firm Braveheart Bio hit the public markets on Thursday after raising $383 million in its upsized initial public offering.

  • August 06, 2026

    Tarsus Bets Up To $800M On Alkeus In Retina Therapy Push

    Tarsus Pharmaceuticals Inc. said Thursday it has agreed to acquire privately held Alkeus Pharmaceuticals Inc. for up to approximately $800 million, expanding the Irvine, California-based eye care company's pipeline into retinal disease with an experimental treatment for Stargardt disease.

  • August 06, 2026

    Eli Lilly, Novo Nordisk Antitrust Suit Tossed By Texas Judge

    A Texas federal court has dismissed compounding pharmacy Strive Specialties Inc.'s antitrust lawsuit against Eli Lilly and Novo Nordisk, finding it failed to allege the companies blocked competition for GLP-1 medications.

Expert Analysis

  • 3 Cases Highlight SEC Distinction Between Exec, Co. Liability

    Author Photo

    Three recent enforcement actions against Spero Therapeutics, Lottery.com and Archer-Daniels-Midland demonstrate that while public companies are subject to liability for misrepresentations, the U.S. Securities and Exchange Commission is focused on individual liability when disclosure violations involve so-called half-truths, say attorneys at Cooley.

  • AI-Generated Doc Ruling Guides Attys On Privilege Risks

    Author Photo

    A New York federal court's ruling, in U.S. v. Heppner, that documents created by a defendant using an artificial intelligence tool were not privileged, can serve as a guide to attorneys for retaining attorney-client or work-product privilege over client documents created with AI, say attorneys at Sher Tremonte.

  • The Law Firm Merger Diaries: Leadership Strategy After Day 1

    Author Photo

    For law firm leaders, ensuring a newly combined law firm lives up to its promise, both in its first days of operation and well after, includes tough decisions, clear and specific communication, and cheerleading, says Peter Michaud at Ballard Spahr.

  • Record FCA Recoveries Signal Intensified Healthcare Focus

    Author Photo

    In its recently released False Claims Act statistics, the U.S. government's emphasis on record healthcare recoveries and government-initiated healthcare matters last year indicates robust enforcement ahead, though the administration's focus on current policy objectives also extends beyond the healthcare sector, say attorneys at Epstein Becker.

  • Fed. Circ. In Jan.: On The Validity Of Expert Testimony

    Author Photo

    The Federal Circuit's recent decision in Barry v. DePuy, addressing whether expert testimony is admissible even if it does not strictly adhere to the court's claim construction, suggests that exclusion via a Daubert motion is appropriate only when the line to improper testimony is clearly crossed, say attorneys at Knobbe Martens.

  • Calif.'s Civility Push Shows Why Professionalism Is Vital

    Author Photo

    The California Bar’s campaign against discourteous behavior by attorneys, including a newly required annual civility oath, reflects a growing concern among states that professionalism in law needs shoring up — and recognizes that maintaining composure even when stressed is key to both succeeding professionally and maintaining faith in the legal system, says Lucy Wang at Hinshaw.

  • A Potential Shift In FDA's Approach To Drug Trial Design

    Author Photo

    Recent guidance released by the U.S. Food and Drug Administration clarifying how Bayesian approaches — which combine prior knowledge with new data — may be used in clinical trials reflects the agency's continued interest in innovative trial designs that may accelerate drug approvals, say attorneys at Alston & Bird.

  • Series

    Trivia Competition Makes Me A Better Lawyer

    Author Photo

    Playing trivia taught me to quickly absorb information and recognize when I've learned what I'm expected to know, training me in the crucial skills needed to be a good attorney, and reminding me to be gracious in defeat, says Jonah Knobler at Patterson Belknap.

  • What FDA Guidance Means For Future Of Health Software

    Author Photo

    Two significant final guidance documents released by the U.S. Food and Drug Administration last month reflect a targeted effort to ease innovation friction around specific areas, including singular clinical decision support recommendations and sensor-based wearables, while maintaining established regulatory boundaries, say attorneys at Covington.

  • Opinion

    Federal Preemption In AI And Robotics Is Essential

    Author Photo

    Federal preemption offers a unified front at a decisive moment that is essential for safeguarding America's economic edge in artificial intelligence and robotics against global rivals, harnessing trillions of dollars in potential, securing high-skilled jobs through human augmentation, and defending technological sovereignty, says Steven Weisburd at Shook Hardy.

  • Series

    Law School's Missed Lessons: What Cross-Selling Truly Takes

    Author Photo

    Early-career attorneys may struggle to introduce clients to practitioners in other specialties, but cross-selling becomes easier once they know why it’s vital to their first years of practice, which mistakes to avoid and how to anticipate clients' needs, say attorneys at Moses & Singer.

  • Drafting Tech Patents After USPTO's Eligibility Memos

    Author Photo

    Two recent U.S. Patent and Trademark Office memos on subject matter eligibility declarations provide an evidentiary playbook for artificial intelligence and software patent applications, highlighting how targeted, stand‑alone SMEDs that present objective, claim‑anchored facts can improve patent application outcomes, say attorneys at Reed Smith.

  • How State FCA Activity May Affect Civil Fraud Enforcement

    Author Photo

    A growing trend of state attorneys general enforcing their False Claims Act analogues independently of the U.S. Department of Justice carries potential repercussions for civil fraud enforcement and qui tam litigation considerations, say Li Yu at Bernstein Litowitz, Ellen London at London & Naor and Gwen Stamper at Vogel Slade.

  • Series

    Judges On AI: Practical Use Cases In Chambers

    Author Photo

    U.S. Magistrate Judge Allison Goddard in the Southern District of California discusses how she uses generative artificial intelligence tools in chambers to make work more efficient and effective — from editing jury instructions for clarity to summarizing key documents.

  • Assessing Compliance Risks Around TrumpRx Participation

    Author Photo

    As there are novel compliance obligations and potential political opposition related to the new TrumpRx online drug platform, companies intending to participate on the site should consider the pressure points that are likely to draw enforcement scrutiny, say attorneys at Sheppard.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.